AtriCure Company Profile (NASDAQ:ATRC)

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ATRC
  • CUSIP: 04963C20
  • Web: www.atricure.com
Capitalization:
  • Market Cap: $703.02 million
  • Outstanding Shares: 33,946,000
Average Prices:
  • 50 Day Moving Avg: $20.81
  • 200 Day Moving Avg: $18.78
  • 52 Week Range: $13.45 - $23.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.38
  • P/E Growth: -1.11
Sales & Book Value:
  • Annual Revenue: $160.44 million
  • Price / Sales: 4.38
  • Book Value: $4.74 per share
  • Price / Book: 4.37
Profitability:
  • EBIDTA: ($21,000,000.00)
  • Net Margins: -23.78%
  • Return on Equity: -19.84%
  • Return on Assets: -13.01%
Debt:
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 3.19%
  • Quick Ratio: 2.47%
Misc:
  • Average Volume: 188,566 shs.
  • Beta: 0.54
  • Short Ratio: 14.6
 

Frequently Asked Questions for AtriCure (NASDAQ:ATRC)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) released its earnings results on Thursday, May, 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.01. The business had revenue of $41.30 million for the quarter, compared to analyst estimates of $40.25 million. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. The company's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.31) earnings per share. View AtriCure's Earnings History.

When will AtriCure make its next earnings announcement?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for AtriCure.

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

7 equities research analysts have issued 12-month target prices for AtriCure's shares. Their predictions range from $17.00 to $25.00. On average, they expect AtriCure's share price to reach $21.57 in the next twelve months. View Analyst Ratings for AtriCure.

What are analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:

  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/10/2017)
  • 2. Needham & Company LLC analysts commented, "ATRC’s 1Q17 revenue, EBITDA, and EPS beat consensus and management maintained its 2017 guidance. Worldwide Open-Heart Ablation growth improved to 10% from 7% in 4Q16 and US Open-Heart Ablation growth increased to 12% from 1% in 4Q16. We think that the improved Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we expect the new guidelines for ablation in concomitant open-heart procedures to drive stronger growth over time. ATRC shares remain at a large discount to peers (2017E EV/ sales of 4.0x vs. small/mid-cap growth peers at a median of 5.8x) and we reiterate our Buy rating." (5/5/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:

  • Richard M. Johnston, Independent Chairman of the Board
  • Michael H. Carrel, President, Chief Executive Officer, Director
  • M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
  • Douglas J. Seith, Chief Operating Officer
  • Vinayak Doraiswamy Ph.D., Senior Vice President - Clinical, Regulatory and Scientific Affairs
  • Andrew L. Lux Ph.D., Senior Vice President - R&D, Operations and QA
  • Patricia J. Kennedy, Vice President, General Manager - International
  • Mark A. Collar, Independent Director
  • Scott William Drake, Independent Director
  • Regina E. Groves, Independent Director

Who owns AtriCure stock?

AtriCure's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (0.00%), Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), Victory Capital Management Inc. (0.00%), Peregrine Capital Management LLC (2.98%) and Loomis Sayles & Co. L P (0.00%). Company insiders that own AtriCure stock include Andrew L Lux, Douglas J Seith and Elizabeth D Krell. View Institutional Ownership Trends for AtriCure.

Who sold AtriCure stock? Who is selling AtriCure stock?

AtriCure's stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Paradigm Capital Management Inc. NY, Royce & Associates LP, Blair William & Co. IL, Credit Suisse AG, Morgan Stanley, Victory Capital Management Inc. and Axiom International Investors LLC DE. Company insiders that have sold AtriCure stock in the last year include Andrew L Lux and Elizabeth D Krell. View Insider Buying and Selling for AtriCure.

Who bought AtriCure stock? Who is buying AtriCure stock?

AtriCure's stock was acquired by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Loomis Sayles & Co. L P, Wellington Management Group LLP, FMR LLC, Peregrine Capital Management LLC, Vanguard Group Inc., Wells Fargo & Company MN and Lockheed Martin Investment Management Co.. View Insider Buying and Selling for AtriCure.

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of AtriCure stock can currently be purchased for approximately $20.71.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $21.57 (4.16% upside)

Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/5/2017Needham & Company LLCReiterated RatingBuy$23.00 -> $25.00HighView Rating Details
4/17/2017Canaccord GenuityReiterated RatingBuy$22.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00 -> $17.00N/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
8/5/2016Stifel NicolausLower Price TargetBuy$26.00 -> $21.00N/AView Rating Details
10/6/2015Leerink SwannReiterated RatingBuyN/AView Rating Details
7/28/2015Dougherty & CoBoost Price TargetBuy$25.00 -> $30.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for AtriCure (NASDAQ:ATRC)
Earnings by Quarter for AtriCure (NASDAQ:ATRC)
Earnings History by Quarter for AtriCure (NASDAQ:ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.32)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AtriCure (NASDAQ:ATRC)
2017 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 79.30%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.00View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.00View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
Source:
DateHeadline
finance.yahoo.com logoAtriCure to Present at the JMP Securities Life Science Conference
finance.yahoo.com - May 18 at 12:03 PM
americanbankingnews.com logoElizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - May 17 at 7:47 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 6:32 PM
finance.yahoo.com logoETFs with exposure to AtriCure, Inc. : May 12, 2017
finance.yahoo.com - May 12 at 4:16 PM
finance.yahoo.com logoAtriCure, Inc. :ATRC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 8:53 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 7:36 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 10:28 PM
americanbankingnews.com logo Brokerages Anticipate AtriCure Inc. (ATRC) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - May 9 at 8:28 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 9:25 AM
americanbankingnews.com logoNeedham & Company LLC Reaffirms "Buy" Rating for AtriCure Inc. (ATRC)
www.americanbankingnews.com - May 6 at 2:04 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoHere's Why ArtiCure, Inc. Is Up Double-Digits Today
finance.yahoo.com - May 5 at 3:44 PM
finance.yahoo.com logoEdited Transcript of ATRC earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 3:44 PM
finance.yahoo.com logoAtriCure Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 8:48 PM
finance.yahoo.com logoAtriCure reports 1Q loss
finance.yahoo.com - May 4 at 8:48 PM
americanbankingnews.com logoAtriCure (ATRC) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 2 at 12:20 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 2 at 9:58 AM
seekingalpha.com logoThoughts On Consonance Capital's Positions - Part 2
seekingalpha.com - April 30 at 2:19 AM
americanbankingnews.com logoAtriCure (ATRC) Receives Media Impact Rating of 0.16
www.americanbankingnews.com - April 29 at 9:58 AM
finance.yahoo.com logoAtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
finance.yahoo.com - April 25 at 11:22 AM
americanbankingnews.com logoAtriCure (ATRC) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 6:00 PM
americanbankingnews.com logoAtriCure (ATRC) Earns Media Sentiment Rating of 0.06
www.americanbankingnews.com - April 20 at 3:25 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Expected to Announce Quarterly Sales of $40.34 Million
www.americanbankingnews.com - April 20 at 10:01 AM
americanbankingnews.com logo Brokerages Anticipate AtriCure Inc. (ATRC) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 19 at 12:15 AM
americanbankingnews.com logoAtriCure's (ATRC) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 17 at 9:10 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Unlikely to Impact AtriCure (ATRC) Stock Price
www.americanbankingnews.com - April 17 at 4:04 PM
americanbankingnews.com logoAtriCure (ATRC) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 5:21 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 14 at 10:41 AM
finance.yahoo.com logoAtriCure to Announce First Quarter 2017 Financial Results
finance.yahoo.com - April 7 at 8:42 PM
finance.yahoo.com logoETFs with exposure to AtriCure, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:12 AM
americanbankingnews.com logoCanaccord Genuity Reaffirms "Buy" Rating for AtriCure Inc. (ATRC)
www.americanbankingnews.com - April 2 at 11:06 AM
bizjournals.com logoAtriCure founder exits amid board reset
www.bizjournals.com - March 24 at 4:05 PM
americanbankingnews.com logoAndrew L. Lux Sells 20,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 21 at 7:37 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Earns "Buy" Rating from Northland Securities
www.americanbankingnews.com - March 20 at 1:42 PM
americanbankingnews.com logoAtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 20 at 1:22 PM
finance.yahoo.com logoAtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
finance.yahoo.com - March 14 at 6:56 AM
thestreet.com logoAtriCure To Present At The Needham & Company's 16th Annual Healthcare Conference
www.thestreet.com - March 11 at 3:40 PM
thestreet.com logoAtriCure To Present At The Needham & Company's 16th Annual Healthcare Conference
www.thestreet.com - March 11 at 3:40 PM
finance.yahoo.com logoAtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
finance.yahoo.com - March 10 at 4:30 PM
nasdaq.com logoMid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital
www.nasdaq.com - March 7 at 8:47 PM
finance.yahoo.com logoAtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
finance.yahoo.com - March 6 at 11:02 AM
biz.yahoo.com logoATRICURE, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 2 at 3:57 PM
us.rd.yahoo.com logo4:08 pm AtriCure beats by $0.05, reports revs in-line with consensus and pre-announcement; guides FY17 EPS below consensus, revs above consensus
us.rd.yahoo.com - March 1 at 8:43 PM
biz.yahoo.com logoAtriCure Inc Earnings Call scheduled for 4:30 pm ET today
us.rd.yahoo.com - March 1 at 8:43 PM
biz.yahoo.com logoATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 1 at 6:24 AM
biz.yahoo.com logoQ4 2016 AtriCure Inc Earnings Release - After Market Close
biz.yahoo.com - February 28 at 11:16 AM
streetinsider.com logoAtriCure (ATRC) Offer Prelim. Q4 Results
www.streetinsider.com - February 3 at 8:51 PM
finance.yahoo.com logoCORRECTING and REPLACING AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - February 3 at 3:51 PM
finance.yahoo.com logoAtriCure to Present at the Leerink Partners Global Healthcare Conference
finance.yahoo.com - January 24 at 4:10 PM
biz.yahoo.com logoATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
biz.yahoo.com - January 9 at 4:49 PM

Social

Chart

AtriCure (ATRC) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff